Series B

A new device gets the CE Mark to modernize a 60-year-old cardiac test, promising clearer, faster diagnosis of shunts linked to stroke in millions.

Raising $100M led by Sequoia, Parallel Web Systems is building the critical infrastructure for AI agents, reshaping how industries access the internet.

A $10T wave of business sales is coming. A new partnership aims to de-risk these deals for everyday entrepreneurs with insurance once reserved for Wall Street.

Ostium's new decentralized execution layer leverages institutional partners like Jump to offer a transparent, on-chain alternative to the $10T CFD market.

AI Council 2026 reveals the industry's next chapter: European founders are flocking to SF, engineering is being reinvented, and video is set to break everything.

After a $700M exit with Peakon and leading a space-tech venture, serial entrepreneur Phil Chambers brings deep operational expertise to Balderton.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

Kensington Capital's sixth SPAC begins trading its warrants separately, signaling the next phase in its search for a high-growth automotive or AI company.

Harrington Discovery Institute opens its 2027 award call, offering millions in funding and expert support to turn academic research into life-saving medicines.

Biotech veteran Habib Dable, who led Acceleron to an $11.5B Merck sale, joins Tyra Biosciences' board, signaling a major push toward commercialization.

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

A luxury brand and an NGO award women in bio-tech and MedTech, tackling the stark funding gap and championing a new generation of impact-driven founders.

The deal accelerates Sanas's infrastructure-first strategy, adding key tech and a serial entrepreneur to rewire how real-time speech AI operates at scale.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

A high-level visit to General Atomics signals a major U.S. push for fusion energy, blending private innovation with public funding to win a global race.

After a massive reverse stock split and a tumultuous offering, Linkers Industries finalizes its capital overhaul. Is this a strategic reset or a crisis averted?

A new partnership combines local infrastructure with global expertise, aiming to streamline development for startups and solidify Singapore's biotech leadership.

Five new clinical trials in Chicago repurpose existing drugs for PTSD, cancer, and more, offering a faster, cheaper path to treating unsolved diseases.

Brands are disappearing from new AI search engines. A new discipline called 'Machine Relations' aims to solve this 'AI invisibility' crisis.